简介：Colorectalcancer(CRC)isasignificantcauseofmorbidityandmortalityworldwide.However,coloncancerincidenceandmortalityisdecliningoverthepastdecadeowingtoadoptionofeffectivescreeningprograms.Nevertheless,insomepartsoftheworld,CRCincidenceandmortalityremainontherise,likelyduetofactorsincluding'westernized'diet,lifestyle,andlackofhealth-careinfrastructureandresources.Participationandadherencetodifferentnationalscreeningprogramsremainobstacleslimitingtheachievementofscreeninggoals.Differentmodalitiesareavailablerangingfromstoolbasedteststoradiologyandendoscopywithvaryingsensitivityandspecificity.However,theavailabilityofthesetestsislimitedtoareaswithhigheconomicresources.Recently,FDAapprovedablood-basedtest(Epiprocolon?)forCRCscreening.Thisbloodbasedtestmayservetoincreasetheparticipationandadherencerates.Hence,leadingtoincreaseincoloncancerdetectionandprevention.ThisarticlewilldiscussvariousCRCscreeningtestswithaparticularfocusonthedataregardingthenewapprovedbloodtest.Finally,wewillproposeanalgorithmforasimplecost-effectiveCRCscreeningprogram.

简介：瞄准：为了学习敏感，特性和钡餐的费用有效性，直与在开发国家钠起源的长期的腹的疼痛地为病人用作一种屏蔽形式的结肠积气(BMFTP)列在后面。方法：出席肠胃病学单位的五十个病人，SMS医院，其临床的评估揭示了肠起源的长期的腹的疼痛，在学习被包括。在平淡的测试以后，BMFT，BMFTP，对比腹部，钡灌肠和结肠镜检查的提高的计算断层摄影术(CECT)被执行。敏感，特性和在小或大的肠损害的察觉的这些成像形式的费用有效性被比较。结果：从五十个病人，结构的病理在十被发现。当七与小肠参与独自或在联合有结肠的参与时，九从这十个病人有小肠参与。当检测小肠参与时，BMFTP的敏感与BMFT是与88.89%相比的100%(BMFTP与回盲肠检测了一个另外的病人参与)。为结肠的病理的察觉的BMFTP的敏感和特性是85.71%和95.35%(41/43)分别地。当他们的敏感是几乎可比较的时，多于BMFTP显著地用BMFT和钡灌肠费用的联合长期的腹的疼痛(肠起源)地屏蔽一个病人。结论：BMFTP应该在研究工作被包括在上面有钠起源的长期的腹的疼痛的病人，在此也多重的地点(小并且大肠)被怀疑参与或这个地点在临床的根据上是不清楚的。BMFTP是排除的一个节俭、快、舒适的过程对在病人的多数的结肠镜检查的需要。

简介：AIMToevaluatewhetherindividualswithgastriccancer（GC）arediagnosedearlieriftheyhavefirstdegreerelativeswithGC.METHODS：Atotalof4282patientsdiagnosedwithGCatNationalCancerCenterHospitalfrom2002to2012wereenrolledinthisretrospectivestudy.Weclassifiedthepatientsaccordingtopresenceorabsenceoffirst-degreefamilyhistoryofGCandcomparedageatdiagnosisandclinicopathologiccharacteristics.Inaddition,wefurtherclassifiedpatientsaccordingtospecificfamilymemberwithGC（father,mother,sibling,oroffspring）andcomparedageatGCdiagnosisamongthesepatientgroups.Baselinecharacteristicswereobtainedfromaprospectivelycollecteddatabase.Informationaboutthefamilymember＇sageatGCdiagnosiswasobtainedbyquestionnaire.RESULTS：Atotalof924patients（21.6%）hadafirstdegreefamilyhistoryofGC.ThemeanageatGCdiagnosisinpatientshavingpaternalhistoryofGCwas54.4±10.4yearsandwassignificantlyyoungerthaninthosewithoutafirst-degreefamilyhistory（58.1±12.0years,P〈0.001）.However,thisfindingwasnotobservedinpatientswhohadanaffectedmother（57.2±10.0years）orsibling（62.2±9.8years）.Amongpatientswithfamilymemberhavingearly-onsetGC（〈50yearsold）,meanageatdiagnosiswas47.7±10.3yearsforthosewithanaffectedfather,48.6±10.4yearsforthosewithanaffectedmother,and57.4±11.5yearsforthosewithanaffectedsibling.Thus,patientswithaparentdiagnosedbefore50yearsofagedevelopedGC10.4or9.5yearsearlierthanindividualswithoutafamilyhistoryofGC（bothP〈0.001）CONCLUSION：Early-onsetGCbeforeageof50wasassociatedwithparentalhistoryofearly-onsetofGC.Individualhavingsuchfamilyhistoryneedtostartscreeningearlier.